ABSTRACT
Patients with cancer are at high risk for thrombosis as well as hemorrhagic complications (1). According to previous observations, venous thromboembolism (VTE) is more frequent in patients with solid tumors, whereas hemorrhage and also uncompensated disseminated intravascular coagulation (DIC) are more frequent with hematologic malignancies, particularly acute leukemias (2,3). However, recent studies indicate that the rate of VTE in acute leukemias and lymphomas is comparable to that of other “highrisk” types of cancers (4). In addition, in a large population study, acute myeloblastic leukemia and non-Hodgkin lymphoma were among the types of malignancies most
frequently preceded by an idiopathic VTE episode in the year immediately before their diagnosis (5).
